United States Drug Patent 5,916,893: Claim Scope, Expiration, and Famciclovir Patent Landscape

U.S. Patent No. 5,916,893 covered post-infection administration of famciclovir, penciclovir, or related derivatives to reduce herpes-virus latency or later reactivation. The claims focused on HSV-1 and HSV-2, delayed treatment beginning more than 18 hours after infection, specified famciclovir doses, and treatment periods of three to 14 days. The patent issued June 29, 1999 and expired June 29, 2016. It no longer creates a U.S. patent barrier to generic famciclovir or penciclovir products.

The patent was a method-of-use patent, not a basic compound patent. Its commercial importance was tied to the clinical proposition that antiviral treatment could remain effective after the initial infection had progressed toward latency.

What does U.S. Patent 5,916,893 cover?

U.S. Patent 5,916,893 covers methods for treating, reducing, or preventing latent herpes-virus infection by administering an effective amount of a compound within the claimed acyclic nucleoside family. The claims specifically identify famciclovir and penciclovir.

Claim group	Subject matter	Principal limitation
Claims 1-8	Treatment of latent herpes-virus infection	Administration more than 18 hours after infection
Claims 2 and 3	HSV-1 and HSV-2	Virus-specific species claims
Claims 4-5	Famciclovir treatment	Specified doses and dosing frequency
Claims 6-7	Timing and duration	At least four days post-infection in claim 6; three to 14 days in claim 7
Claim 8	Penciclovir	Compound-specific claim
Claims 9-15	Reduction or prevention of latency and subsequent reactivation	Famciclovir or penciclovir administered more than 18 hours after infection

The patent’s operative concept was delayed antiviral intervention. The claims did not require treatment immediately after exposure or at the first clinical symptom. They required administration after the stated post-infection threshold.

How should the claims of Patent 5,916,893 be construed?

Claim 1: broad genus method claim

Claim 1 requires:

A human patient.
A latent herpes-virus infection.
Administration of an effective amount.
A compound of Formula A, a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester, or acyl derivative.
Administration more than 18 hours after infection.

The claim is broader than the later compound-specific claims because it covers a chemical genus and several derivative categories. “Bioprecursor” is directed to a compound converted in vivo to the active antiviral. Famciclovir is the principal commercial example because it is converted to penciclovir after administration.

The claim does not require a specific route of administration, formulation, disease severity, anatomical site, or laboratory method for confirming latency. It also does not expressly require that the infection be clinically symptomatic.

Claims 2 and 3: HSV-specific limitations

Claims 2 and 3 narrow claim 1 to latent HSV-1 and HSV-2 infections. These claims are technically narrower but commercially more relevant because famciclovir was marketed for herpesvirus indications including recurrent genital herpes and herpes labialis.

A product or treatment protocol would need to satisfy the underlying timing and latency limitations. Merely administering famciclovir for an active HSV outbreak would not automatically practice these claims unless the treatment also fell within the latent-infection limitations.

Claims 4 and 5: famciclovir and dose limitations

Claim 4 identifies famciclovir as the administered compound. Claim 5 limits the regimen to 125 mg, 250 mg, 500 mg, 750 mg, or 1 gram, administered once, twice, or three times daily.

These dose limitations were commercially significant because they corresponded to conventional famciclovir tablet strengths and clinical regimens. The claim language does not, however, require a particular tablet strength, excipient system, package, or release profile. A formulation would be relevant only if the resulting administration met the claimed dose and method conditions.

Claims 6 and 7: timing and treatment duration

Claim 6 requires administration four or more days after infection. This is narrower than the more-than-18-hour requirement in claim 1.

Claim 7 requires a three- to 14-day period for reduction of latency or reactivation. The claim is unusual because it ties the method to the duration of the claimed biological result rather than simply to a fixed dosing schedule.

Claims 8-15: penciclovir and prevention of reactivation

Claim 8 separately identifies penciclovir. Claims 9-15 recast the invention as prevention or reduction of herpes virus becoming latent and later reactivating.

Claims 9 and 10-11 cover famciclovir or penciclovir for HSV-1 and HSV-2. Claims 12 and 13 specify famciclovir doses and frequencies. Claim 14 repeats the four-day-or-greater timing limitation, and claim 15 repeats the three- to 14-day duration limitation.

What are the key infringement elements?

A direct method-of-use infringement theory would require evidence that the accused party’s treatment protocol satisfies each required element.

Element	Practical evidence
Human patient	Label, clinical protocol, prescription record
HSV infection	Diagnostic record, trial inclusion criteria, virologic testing
Latent infection or prevention of latency	Clinical endpoint, study protocol, biological rationale
Famciclovir or penciclovir	Product identity and active ingredient
Effective amount	Dose and treatment record
More than 18 hours post-infection	Timing data, trial protocol, patient history
Four or more days post-infection	Required for claims 6 and 14
Three- to 14-day outcome period	Required for claims 7 and 15

The “more than 18 hours post-infection” limitation presents a substantial proof issue. In ordinary clinical practice, the precise time of HSV infection is usually unknown. Patients commonly present with symptoms rather than a documented infection event. That distinction could make infringement difficult to establish for routine commercial prescriptions.

The latency limitations create a second issue. A prescription for recurrent genital herpes, cold sores, or herpes zoster does not necessarily establish that the drug was administered to prevent establishment of latency or to prevent later reactivation.

When did U.S. Patent 5,916,893 expire?

U.S. Patent 5,916,893 expired on June 29, 2016, based on the 17-year patent term applicable to the patent’s filing history and issue date. The U.S. Patent and Trademark Office treats an expired patent as unenforceable against later conduct. The patent therefore cannot currently block generic manufacture, sale, or use in the United States (U.S. Patent and Trademark Office, n.d.-a).

Event	Date
Patent issued	June 29, 1999
Patent term endpoint	June 29, 2016
Current status	Expired
Current U.S. enforcement value	None

The expiration eliminates patent-term protection, but it does not erase historical exposure. Conduct occurring before expiration could remain relevant to a properly preserved claim, subject to limitations periods, prosecution history, validity defenses, and other litigation requirements.

What was the FDA and Orange Book status?

Patent 5,916,893 was not the basic regulatory foundation for famciclovir approval. FDA approval concerned Famvir, the branded product containing famciclovir. The patent covered a treatment method involving latency and reactivation, while the FDA label addressed approved clinical indications and dosing regimens.

FDA Orange Book relevance depends on whether a patent is submitted by the NDA holder and accepted for listing as a patent claiming the drug substance, drug product, or an approved method of use. A method patent is not automatically listed merely because it concerns an FDA-approved active ingredient (U.S. Food and Drug Administration, n.d.-a).

The practical distinction is:

A listed method patent can support a Paragraph IV certification and patent litigation by an NDA holder.
An unlisted or expired patent does not create a current Orange Book block.
A label carve-out may avoid an approved method-of-use patent where the generic product has other noninfringing uses.
FDA approval does not validate the patent or extend its term.

Famciclovir products have long been subject to generic competition. The FDA labeling for Famvir identifies famciclovir as the prodrug of penciclovir and provides dosing for herpes zoster, recurrent genital herpes, suppression of recurrent genital herpes, and recurrent herpes labialis (U.S. Food and Drug Administration, n.d.-b).

Were Paragraph IV challenges relevant to this patent?

Paragraph IV challenges were potentially relevant while the patent was unexpired and listed for an approved method of use. A generic applicant could assert that:

The patent was invalid.
The patent was unenforceable.
The proposed generic product would not infringe.
The relevant indication could be omitted from the generic label.

For Patent 5,916,893, a Paragraph IV theory would likely focus on the unusual post-infection timing and latency limitations. A generic applicant could distinguish ordinary treatment of active HSV lesions from the claimed prevention or reduction of latent infection.

The patent’s expiration in 2016 means that a current abbreviated new drug application does not need to overcome this patent as an enforceable U.S. barrier. Any historical Paragraph IV dispute would need to be evaluated through the FDA litigation records and the relevant NDA patent-listing history.

What patents protected famciclovir and penciclovir beyond Patent 5,916,893?

Patent 5,916,893 was one part of a broader antiviral patent estate. The relevant categories were:

Compound and active-metabolite patents

Earlier patents covered penciclovir and related acyclic guanine nucleosides. These patents generally addressed the chemical entity, salts, stereochemical forms, or antiviral activity of the compound.

Prodrug patents

Famciclovir is an orally bioavailable diacetate prodrug of penciclovir. Prodrug claims could protect the specific esterified structure, pharmaceutical use, or conversion to penciclovir.

Formulation patents

Formulation protection could cover tablets, particle size, excipients, stability, dissolution, or manufacturing parameters. Patent 5,916,893 does not claim a particular famciclovir formulation. It is therefore distinct from a formulation patent that requires a specific composition.

Method-of-use patents

Patent 5,916,893 is principally a method-of-use patent. Its differentiating feature is treatment after infection has progressed beyond the initial period, with an objective of reducing latency or reactivation.

Manufacturing and process patents

Process patents could cover synthesis, purification, crystalline forms, intermediates, or impurity control. Such patents may create manufacturing barriers even after a use patent expires, although they cannot extend the expired term of Patent 5,916,893.

Protection type	Relevance to famciclovir	Status of Patent 5,916,893
Compound	Protects active chemical entity	Not the principal claim type
Prodrug	Protects famciclovir structure or conversion	Separate estate
Formulation	Protects dosage form or excipient system	Not claimed in detail
Method of use	Protects treatment indication or timing	Core subject matter
Manufacturing	Protects synthesis and purification	Separate estate

How strong was the patent estate?

Patent 5,916,893 had moderate historical scope but limited present value because of expiration and claim-specific proof requirements.

Strengths

Express coverage of famciclovir and penciclovir.
Specific claims directed to HSV-1 and HSV-2.
Coverage of delayed administration, which could distinguish immediate-treatment prior art.
Dose and timing claims that mapped to clinical use.
Claims directed to preventing latent infection and later reactivation.

Weaknesses

The precise infection time may be difficult to establish clinically.
“Latent infection” and “reactivation” can require specialized virologic evidence.
The claims may face written-description and enablement scrutiny across broad compound and herpes-virus categories.
Routine treatment of active herpes lesions may fall outside the latency-focused limitations.
The patent expired in 2016.

The strongest historical claims were likely claims 4, 5, 8, 9, and 12-15 when the administered product, timing, dose, and treatment objective were documented. Claims 1 and 9 had broader conceptual coverage but also carried more construction and proof issues.

What litigation or settlement exposure remains?

No current enforceable exclusionary right arises from Patent 5,916,893 because the patent expired. A historical litigation review should distinguish:

Patent 5,916,893 itself.
Other famciclovir compound, formulation, or process patents.
FDA Hatch-Waxman litigation involving Famvir.
Private license or settlement agreements involving earlier patents.
Any damages claims for conduct before June 29, 2016.

The patent record should be reviewed through USPTO Patent Center, PACER, FDA Orange Book archives, and the FDA Paragraph IV database. A settlement concerning another Famvir patent would not automatically affect the scope or enforceability of Patent 5,916,893.

What generic launch risks exist for famciclovir?

The patent-specific risk from Patent 5,916,893 is zero for a new U.S. launch because the patent is expired. Remaining launch risks would arise from:

FDA approval requirements for famciclovir tablets.
Bioequivalence and pharmaceutical-equivalence requirements.
Other unexpired patents, if any.
Manufacturing-process rights.
Trademark and trade-dress restrictions.
Regulatory exclusivity, if applicable to a particular supplemental approval.
Product liability and pharmacovigilance obligations.

Famciclovir is a small-molecule product. Biosimilar regulation does not apply. A generic applicant would use the abbreviated new drug application pathway rather than the biologics license application and biosimilar pathway.

How does Patent 5,916,893 compare with competing antiviral estates?

Drug	Active ingredient	Patent type most relevant to competition	Biosimilar risk
Famvir	Famciclovir	Compound, prodrug, formulation, method of use	None
Valtrex	Valacyclovir	Prodrug, formulation, method of use	None
Zovirax	Acyclovir	Compound, formulation, method of use	None
Denavir	Penciclovir	Topical formulation and use	None

Famciclovir competes primarily with valacyclovir and acyclovir. The products have overlapping herpesvirus indications but different pharmacokinetic profiles, dosing schedules, formulations, and legacy patent estates. Patent 5,916,893 did not cover valacyclovir or acyclovir.

Key Takeaways

U.S. Patent 5,916,893 covered delayed administration of famciclovir, penciclovir, and related derivatives for reducing herpes-virus latency or reactivation.
The central limitations were administration more than 18 hours after infection, treatment of latent infection, and prevention of subsequent reactivation.
Claims 2, 3, 10, and 11 focused on HSV-1 and HSV-2.
Claims 5, 12, and 13 specified famciclovir doses and dosing frequencies.
The patent expired June 29, 2016.
It is not a current U.S. barrier to generic famciclovir or penciclovir.
The patent did not claim a specific tablet formulation, manufacturing process, or broad exclusivity over famciclovir itself.
Historical infringement would have required proof of infection timing, latency or reactivation objectives, drug administration, and the applicable dose.
Famciclovir is a small molecule and has no biosimilar pathway risk.

FAQs

Does Patent 5,916,893 cover all uses of famciclovir?

No. It covered specified methods involving latent herpes-virus infection, delayed administration, and reduction or prevention of reactivation. It did not broadly claim every use of famciclovir.

Could a generic famciclovir manufacturer still infringe Patent 5,916,893?

No, for conduct occurring after expiration. The patent expired June 29, 2016. Other patents or non-patent regulatory requirements could still affect a product.

Does the patent cover valacyclovir?

No. The listed claims identify famciclovir, penciclovir, and related compounds. Valacyclovir is a different prodrug of acyclovir.

Is famciclovir subject to biosimilar competition?

No. Famciclovir is a chemically synthesized small molecule. Competition proceeds through the generic drug pathway, principally an abbreviated new drug application.

Does a standard prescription for recurrent herpes practice the claims?

Not necessarily. The claims require latency-related treatment objectives and post-infection timing. A routine prescription for an active outbreak may not satisfy those limitations.

References

U.S. Patent and Trademark Office. (1999). U.S. Patent No. 5,916,893, Use of penciclovir and famciclovir in the treatment of herpes virus infections. https://patents.google.com/patent/US5916893
U.S. Patent and Trademark Office. (n.d.-a). Patent term adjustment and patent term expiration information. https://www.uspto.gov/patents/laws/term
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (n.d.-b). Famvir prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9425012	Dec 12, 1994
United Kingdom	9506663	Mar 31, 1995
United Kingdom	9517308	Aug 24, 1995

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	669	⤷ Start Trial
African Regional IP Organization (ARIPO)	9701001	⤷ Start Trial
Austria	208198	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,916,893

Summary for Patent: 5,916,893